Cambridge Cognition
The company’s current software assesses the cognitive health of global patients to improve clinical trial outcomes and efficiency with high-accuracy tech solutions that demonstrate sensitivity to biomarkers, effect and brain disease progression.
With over 30 years of scientific innovation, Cambridge Cognition’s digital cognitive assessments provide academic researchers, drug developers, and other industry professionals with groundbreaking solutions that monitor a patient’s cognitive abilities through touch-screen and free-speech and for at-home or in-clinic assessment.
Cambridge Cognition has successfully integrated acquisitions and launched profitable new products for its end-to-end platform for central nervous system clinical trials, and it is planning major growth through 2024.
